The document discusses bacterial infection routes and the immune response to bacteria. It provides details on:
1) Bacteria can enter through the respiratory, gastrointestinal, or genitourinary tracts, or through breaks in skin or mucous membranes. The immune response depends on number and virulence of bacteria.
2) The humoral immune response produces antibodies that remove extracellular bacteria and toxins via phagocytosis, complement activation, and recruitment of immune cells.
3) The cell-mediated response activates NK cells and macrophages against intracellular bacteria via cytokines from CD4+ T cells.
Immunity against microbial infections dr.ihsan alsaimarydr.Ihsan alsaimary
Dr. ihsan edan abdulkareem alsaimary
PROFESSOR IN MEDICAL MICROBIOLOGY AND MOLECULAR IMMUNOLOGY
ihsanalsaimary@gmail.com
mobile : 009647801410838
university of basrah - college of medicine - basrah -IRAQ
Immunity against microbial infections dr.ihsan alsaimarydr.Ihsan alsaimary
Dr. ihsan edan abdulkareem alsaimary
PROFESSOR IN MEDICAL MICROBIOLOGY AND MOLECULAR IMMUNOLOGY
ihsanalsaimary@gmail.com
mobile : 009647801410838
university of basrah - college of medicine - basrah -IRAQ
Mycobacterium is a genus of Actinobacteria, given its own family, the Mycobacteriaceae. Over 190 species are recognized in this genus. This genus includes pathogens known to cause serious diseases in mammals, including tuberculosis (Mycobacterium tuberculosis) and leprosy (Mycobacterium leprae) in humans.
Mycobacterium is a genus of Actinobacteria, given its own family, the Mycobacteriaceae. Over 190 species are recognized in this genus. This genus includes pathogens known to cause serious diseases in mammals, including tuberculosis (Mycobacterium tuberculosis) and leprosy (Mycobacterium leprae) in humans.
TOP AND BEST GLUTE BUILDER A 606 | Fitking FitnessFitking Fitness
"Feature:
• Intelligent Ergonomically Design Glute Builder Is A Must Have For Those Looking To Target Their Gluteal Muscles And Hamstrings With Precision.
• The Ability To Adjust The Starting Position, This Machine Allows For A More Targeted Workout That Is Tailored To Your Specific Needs.
• Spacious And Supportive Cushioned Seat Provide Added Comfort And Stability During Your Workout."
Get more information visit on:- www.fitking.in
Our mail I.D:-care@fitking.in, fitking.in@gmail.com
Call us at :- 9958880790, 9870336406, 8800695917
India Diagnostic Labs Market: Dynamics, Key Players, and Industry Projections...Kumar Satyam
According to the TechSci Research report titled “India Diagnostic Labs Market Industry Size, Share, Trends, Competition, Opportunity, and Forecast, 2019-2029,” the India Diagnostic Labs Market was valued at USD 16,471.21 million in 2023 and is projected to grow at an impressive compound annual growth rate (CAGR) of 11.55% through 2029. This significant growth can be attributed to various factors, including collaborations and partnerships among leading companies, the expansion of diagnostic chains, and increasing accessibility to diagnostic services across the country. This comprehensive report delves into the market dynamics, recent trends, drivers, competitive landscape, and benefits of the research report, providing a detailed analysis of the India Diagnostic Labs Market.
Collaborations and Partnerships
Collaborations and partnerships among leading companies play a pivotal role in driving the growth of the India Diagnostic Labs Market. These strategic alliances allow companies to merge their expertise, strengthen their market positions, and offer innovative solutions. By combining resources, companies can enhance their research and development capabilities, expand their product portfolios, and improve their distribution networks. These collaborations also facilitate the sharing of technological advancements and best practices, contributing to the overall growth of the market.
Expansion of Diagnostic Chains
The expansion of diagnostic chains is a driving force behind the growing demand for diagnostic lab services. Diagnostic chains often establish multiple laboratories and diagnostic centers in various cities and regions, including urban and rural areas. This expanded network makes diagnostic services more accessible to a larger portion of the population, addressing healthcare disparities and reaching underserved populations. The presence of diagnostic chain facilities in multiple locations within a city or region provides convenience for patients, reducing travel time and effort. A broader network of labs often leads to reduced waiting times for appointments and sample collection, ensuring that patients receive timely and efficient diagnostic services.
Rising Prevalence of Chronic Diseases
The increasing prevalence of chronic diseases is a significant driver for the demand for diagnostic lab services. Chronic conditions such as diabetes, cardiovascular diseases, and cancer require regular monitoring and diagnostic testing for effective management. The rise in chronic diseases necessitates the use of advanced diagnostic tools and technologies, driving the growth of the diagnostic labs market. Additionally, early diagnosis and timely intervention are crucial for managing chronic diseases, further boosting the demand for diagnostic lab services.
ICH Guidelines for Pharmacovigilance.pdfNEHA GUPTA
The "ICH Guidelines for Pharmacovigilance" PDF provides a comprehensive overview of the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) guidelines related to pharmacovigilance. These guidelines aim to ensure that drugs are safe and effective for patients by monitoring and assessing adverse effects, ensuring proper reporting systems, and improving risk management practices. The document is essential for professionals in the pharmaceutical industry, regulatory authorities, and healthcare providers, offering detailed procedures and standards for pharmacovigilance activities to enhance drug safety and protect public health.
CHAPTER 1 SEMESTER V - ROLE OF PEADIATRIC NURSE.pdfSachin Sharma
Pediatric nurses play a vital role in the health and well-being of children. Their responsibilities are wide-ranging, and their objectives can be categorized into several key areas:
1. Direct Patient Care:
Objective: Provide comprehensive and compassionate care to infants, children, and adolescents in various healthcare settings (hospitals, clinics, etc.).
This includes tasks like:
Monitoring vital signs and physical condition.
Administering medications and treatments.
Performing procedures as directed by doctors.
Assisting with daily living activities (bathing, feeding).
Providing emotional support and pain management.
2. Health Promotion and Education:
Objective: Promote healthy behaviors and educate children, families, and communities about preventive healthcare.
This includes tasks like:
Administering vaccinations.
Providing education on nutrition, hygiene, and development.
Offering breastfeeding and childbirth support.
Counseling families on safety and injury prevention.
3. Collaboration and Advocacy:
Objective: Collaborate effectively with doctors, social workers, therapists, and other healthcare professionals to ensure coordinated care for children.
Objective: Advocate for the rights and best interests of their patients, especially when children cannot speak for themselves.
This includes tasks like:
Communicating effectively with healthcare teams.
Identifying and addressing potential risks to child welfare.
Educating families about their child's condition and treatment options.
4. Professional Development and Research:
Objective: Stay up-to-date on the latest advancements in pediatric healthcare through continuing education and research.
Objective: Contribute to improving the quality of care for children by participating in research initiatives.
This includes tasks like:
Attending workshops and conferences on pediatric nursing.
Participating in clinical trials related to child health.
Implementing evidence-based practices into their daily routines.
By fulfilling these objectives, pediatric nurses play a crucial role in ensuring the optimal health and well-being of children throughout all stages of their development.
Trauma Outpatient Center is a comprehensive facility dedicated to addressing mental health challenges and providing medication-assisted treatment. We offer a diverse range of services aimed at assisting individuals in overcoming addiction, mental health disorders, and related obstacles. Our team consists of seasoned professionals who are both experienced and compassionate, committed to delivering the highest standard of care to our clients. By utilizing evidence-based treatment methods, we strive to help our clients achieve their goals and lead healthier, more fulfilling lives.
Our mission is to provide a safe and supportive environment where our clients can receive the highest quality of care. We are dedicated to assisting our clients in reaching their objectives and improving their overall well-being. We prioritize our clients' needs and individualize treatment plans to ensure they receive tailored care. Our approach is rooted in evidence-based practices proven effective in treating addiction and mental health disorders.
Empowering ACOs: Leveraging Quality Management Tools for MIPS and BeyondHealth Catalyst
Join us as we delve into the crucial realm of quality reporting for MSSP (Medicare Shared Savings Program) Accountable Care Organizations (ACOs).
In this session, we will explore how a robust quality management solution can empower your organization to meet regulatory requirements and improve processes for MIPS reporting and internal quality programs. Learn how our MeasureAble application enables compliance and fosters continuous improvement.
Medical Technology Tackles New Health Care Demand - Research Report - March 2...pchutichetpong
M Capital Group (“MCG”) predicts that with, against, despite, and even without the global pandemic, the medical technology (MedTech) industry shows signs of continuous healthy growth, driven by smaller, faster, and cheaper devices, growing demand for home-based applications, technological innovation, strategic acquisitions, investments, and SPAC listings. MCG predicts that this should reflects itself in annual growth of over 6%, well beyond 2028.
According to Chris Mouchabhani, Managing Partner at M Capital Group, “Despite all economic scenarios that one may consider, beyond overall economic shocks, medical technology should remain one of the most promising and robust sectors over the short to medium term and well beyond 2028.”
There is a movement towards home-based care for the elderly, next generation scanning and MRI devices, wearable technology, artificial intelligence incorporation, and online connectivity. Experts also see a focus on predictive, preventive, personalized, participatory, and precision medicine, with rising levels of integration of home care and technological innovation.
The average cost of treatment has been rising across the board, creating additional financial burdens to governments, healthcare providers and insurance companies. According to MCG, cost-per-inpatient-stay in the United States alone rose on average annually by over 13% between 2014 to 2021, leading MedTech to focus research efforts on optimized medical equipment at lower price points, whilst emphasizing portability and ease of use. Namely, 46% of the 1,008 medical technology companies in the 2021 MedTech Innovator (“MTI”) database are focusing on prevention, wellness, detection, or diagnosis, signaling a clear push for preventive care to also tackle costs.
In addition, there has also been a lasting impact on consumer and medical demand for home care, supported by the pandemic. Lockdowns, closure of care facilities, and healthcare systems subjected to capacity pressure, accelerated demand away from traditional inpatient care. Now, outpatient care solutions are driving industry production, with nearly 70% of recent diagnostics start-up companies producing products in areas such as ambulatory clinics, at-home care, and self-administered diagnostics.
Navigating Challenges: Mental Health, Legislation, and the Prison System in B...Guillermo Rivera
This conference will delve into the intricate intersections between mental health, legal frameworks, and the prison system in Bolivia. It aims to provide a comprehensive overview of the current challenges faced by mental health professionals working within the legislative and correctional landscapes. Topics of discussion will include the prevalence and impact of mental health issues among the incarcerated population, the effectiveness of existing mental health policies and legislation, and potential reforms to enhance the mental health support system within prisons.
For those battling kidney disease and exploring treatment options, understanding when to consider a kidney transplant is crucial. This guide aims to provide valuable insights into the circumstances under which a kidney transplant at the renowned Hiranandani Hospital may be the most appropriate course of action. By addressing the key indicators and factors involved, we hope to empower patients and their families to make informed decisions about their kidney care journey.
Contact ME {89011**83002} Haridwar ℂall Girls By Full Service Call Girl In Ha...
Bacterial infections
1. Routes of Bacterial InfectionRoutes of Bacterial Infection
• Respiratory tractRespiratory tract
• Gastrointestinal TractGastrointestinal Tract
• Genitourinary tractGenitourinary tract
• Unnatural routes openedUnnatural routes opened
up by breaks in mucousup by breaks in mucous
membranes or skinmembranes or skin
• Different levels of hostDifferent levels of host
defense mechanisms aredefense mechanisms are
enlisted depending on theenlisted depending on the
number of organismsnumber of organisms
entering and theirentering and their
virulence.virulence.
2. Immune Response to BacteriaImmune Response to Bacteria
• Extracellular BacteriaExtracellular Bacteria
– Humoral immune responseHumoral immune response
– Humoral antibodies produced by plasma cellsHumoral antibodies produced by plasma cells
in regional lymph nodes and submucosa ofin regional lymph nodes and submucosa of
respiratory and gastrointestinal tractsrespiratory and gastrointestinal tracts
– The antibodies remove the bacteria andThe antibodies remove the bacteria and
inactivate bacterial toxins to protect the hostinactivate bacterial toxins to protect the host
cell from invading organisms.cell from invading organisms.
3. • Antibody neutralizesAntibody neutralizes
bacterial toxinsbacterial toxins
• Complement activationComplement activation
• Antibody andAntibody and
complement split productcomplement split product
C3b bind to bacteria,C3b bind to bacteria,
serving as opsonins toserving as opsonins to
increase phagocytosis.increase phagocytosis.
• C3a and C5a induce localC3a and C5a induce local
mast cell degranulationmast cell degranulation
• Other complement splitOther complement split
products are chemotacticproducts are chemotactic
for neutrophils andfor neutrophils and
macrophages.macrophages.
4. Immune Response to BacteriaImmune Response to Bacteria
• Intracellular BacteriaIntracellular Bacteria
– Cell-mediated immune response (Delayed-Cell-mediated immune response (Delayed-
type hypersensitivity)type hypersensitivity)
– Activate Natural Killer (NK) cells provide earlyActivate Natural Killer (NK) cells provide early
defense against bacteria.defense against bacteria.
5. • In delayed typeIn delayed type
hypersensitivity,hypersensitivity,
cytokines secreted bycytokines secreted by
CD4+ T cells, such asCD4+ T cells, such as
IFN gamma, activateIFN gamma, activate
macrophages to killmacrophages to kill
ingested pathogensingested pathogens
more effectively.more effectively.
6. Bacterial Evasion of Host DefenseBacterial Evasion of Host Defense
MechanismMechanism
• Four Steps in Bacterial InfectionFour Steps in Bacterial Infection
– Attachment to host cellsAttachment to host cells
– ProliferationProliferation
– Invasion of host tissueInvasion of host tissue
– Toxin-induced damage to host cellToxin-induced damage to host cell
Many bacteria have developed ways toMany bacteria have developed ways to
overcome some of these host defenseovercome some of these host defense
mechanismsmechanisms
7.
8. Contribution of the ImmuneContribution of the Immune
Response to BacterialResponse to Bacterial
PathogenesisPathogenesis
• Disease can also be caused by theDisease can also be caused by the
immune response to the pathogen.immune response to the pathogen.
• Pathogen-stimulated overproduction ofPathogen-stimulated overproduction of
cytokines can lead to symptoms ofcytokines can lead to symptoms of
bacterial septic shock, food poisoning, andbacterial septic shock, food poisoning, and
toxic shock syndrome.toxic shock syndrome.
9. Contribution of the ImmuneContribution of the Immune
Response to BacterialResponse to Bacterial
PathogenesisPathogenesis
• Bacteria that can survive intracellularly withinBacteria that can survive intracellularly within
infected cells can result in chronic antigenicinfected cells can result in chronic antigenic
activation of CD4+ T-cells, leading to tissueactivation of CD4+ T-cells, leading to tissue
destruction by a cell-mediated response withdestruction by a cell-mediated response with
characteristics of a delayed type hypersensitivitycharacteristics of a delayed type hypersensitivity
reactionreaction
• Cytokines secreted by CD4+ cells canCytokines secreted by CD4+ cells can
accumulate, leading to the formation ofaccumulate, leading to the formation of
granulomas. The concentrations of lysosomalgranulomas. The concentrations of lysosomal
enzymes in the granulomas can cause tissueenzymes in the granulomas can cause tissue
necrosis.necrosis.
10. Diphtheria (Diphtheria (CorynebacteriumCorynebacterium
diphtheriaediphtheriae))
• Gram positive, rod-likeGram positive, rod-like
organismorganism
• Bacterial disease caused by aBacterial disease caused by a
secreted exotoxin.secreted exotoxin.
• Spread via airborne respiratorySpread via airborne respiratory
dropletsdroplets
• Exotoxin destroys underlyingExotoxin destroys underlying
tissue, forming a tough, fibroustissue, forming a tough, fibrous
membrane compose of fibrin,membrane compose of fibrin,
white blood cells and deadwhite blood cells and dead
respiratory cellsrespiratory cells
• Also responsible for systemicAlso responsible for systemic
manifestations.manifestations.
11. Symptoms of DiphtheriaSymptoms of Diphtheria
• Damage to different organsDamage to different organs
such as the heart, liver,such as the heart, liver,
kidneys and nervous system.kidneys and nervous system.
• Choking layer of bacteria andChoking layer of bacteria and
dead cells in the respiratorydead cells in the respiratory
system, accompanied by ansystem, accompanied by an
unworldly stenchunworldly stench
• Difficulty swallowing andDifficulty swallowing and
breathingbreathing
• Pus and blood dischargePus and blood discharge
through nostrils following deaththrough nostrils following death
from asphyxiationfrom asphyxiation
12. More info on diphtheria……More info on diphtheria……
• The exotoxin is encoded by the tox gene carried byThe exotoxin is encoded by the tox gene carried by
phage B (beta)phage B (beta)
• Some strains can exist in the state of lysogeny.Some strains can exist in the state of lysogeny.
• Exotoxin has two disulfide linked chains, a binding chainExotoxin has two disulfide linked chains, a binding chain
and a toxin chain. The binding chain interacts withand a toxin chain. The binding chain interacts with
ganglioside receptors on susceptible cells, facilitatingganglioside receptors on susceptible cells, facilitating
internalization of the exotoxin.internalization of the exotoxin.
• Inhibitory effect of toxin chain on protein synthesis leadsInhibitory effect of toxin chain on protein synthesis leads
to toxicity.to toxicity.
• Removal of the binding chain prevents exotoxin fromRemoval of the binding chain prevents exotoxin from
entering the cell.entering the cell.
13. How We Treat This Bad Boy….How We Treat This Bad Boy….
• Toxoid prepared by treating diphtheria toxin withToxoid prepared by treating diphtheria toxin with
formaldehyde.formaldehyde.
• Reaction with formaldehyde cross-links the toxin,Reaction with formaldehyde cross-links the toxin,
resulting in loss of toxicity and enhancement in itsresulting in loss of toxicity and enhancement in its
antigenicity.antigenicity.
• Usually administered with tetanus toxoid and inactivatedUsually administered with tetanus toxoid and inactivated
Bordetelal pertussisBordetelal pertussis in a combined vaccine that is givenin a combined vaccine that is given
to children 6-8 weeks of age.to children 6-8 weeks of age.
• Immunization with toxoid induces production ofImmunization with toxoid induces production of
antibodies which bind to the toxin and neutralize itsantibodies which bind to the toxin and neutralize its
activity.activity.
15. Photo Ops of DiphtheriaPhoto Ops of Diphtheria
(Smile!)(Smile!)
16. Tuberculosis (Tuberculosis (MycobacteriumMycobacterium
tuberculosistuberculosis))
• Bacilli shaped organismBacilli shaped organism
• Pulmonary infection by inhalation ofPulmonary infection by inhalation of
small droplets of respiratory secretionssmall droplets of respiratory secretions
containing a few bacillicontaining a few bacilli
• Inhaled bacilli are ingested by alveolarInhaled bacilli are ingested by alveolar
macrophages and multiplymacrophages and multiply
intracellulary by inhibiting formation ofintracellulary by inhibiting formation of
phagolysomes.phagolysomes.
• Macrophages lyse and large numbersMacrophages lyse and large numbers
of bacilli are released.of bacilli are released.
• Cell mediated response by CD4+ TCell mediated response by CD4+ T
cells may be responsible for much ofcells may be responsible for much of
the tissue damage of the disease.the tissue damage of the disease.
• Most common infection of tuberculosisMost common infection of tuberculosis
is pulmonary tuberculosis.is pulmonary tuberculosis.
17. Symptoms of TuberculosisSymptoms of Tuberculosis
• Symptoms of TB depend on whereSymptoms of TB depend on where
in the body the TB bacteria arein the body the TB bacteria are
growing. TB bacteria usually growgrowing. TB bacteria usually grow
in the lungs. TB in the lungs mayin the lungs. TB in the lungs may
causecause
– a bad cough that lasts longera bad cough that lasts longer
than 2 weeksthan 2 weeks
– pain in the chestpain in the chest
– coughing up blood or sputumcoughing up blood or sputum
(phlegm from deep inside the(phlegm from deep inside the
lungs)lungs)
• Other symptoms of TB diseaseOther symptoms of TB disease
areare
– weakness or fatigueweakness or fatigue
– weight lossweight loss
– no appetiteno appetite
– chillschills
– feverfever
– sweating at nightsweating at night
18. Immune Response to TuberculosisImmune Response to Tuberculosis
• Cytokines produced by CD4+ T cells activateCytokines produced by CD4+ T cells activate
macrophages, which kill the bacilli or inhibits theirmacrophages, which kill the bacilli or inhibits their
growth.growth.
• High levels of interleukin-2 (IL-2), produced byHigh levels of interleukin-2 (IL-2), produced by
macrophages, stimulates Th 1-mediated responses.macrophages, stimulates Th 1-mediated responses.
• IL-2 may also contribute to resistance by inducingIL-2 may also contribute to resistance by inducing
production of chemokines that attract macrophages toproduction of chemokines that attract macrophages to
the site of infection.the site of infection.
• CD4+ T cell mediated response mounted by thoseCD4+ T cell mediated response mounted by those
exposed toexposed to M. tuberculosisM. tuberculosis controls the infection andcontrols the infection and
protects against later infection.protects against later infection.
19. Treatment and VaccinesTreatment and Vaccines
• Tuberculosis is treated withTuberculosis is treated with
several drugs includingseveral drugs including
isoniazid, rifampin,isoniazid, rifampin,
streptomycin, pyrazinamide,streptomycin, pyrazinamide,
and ethambutol.and ethambutol.
• Drug therapy must continue forDrug therapy must continue for
at least 9 months to get rid ofat least 9 months to get rid of
the bacteria since thethe bacteria since the
intracellular growth of M.intracellular growth of M.
tuberculosis makes it difficulttuberculosis makes it difficult
for the drugs to reach thefor the drugs to reach the
bacilli.bacilli.
• Vaccine : attenuated strain ofVaccine : attenuated strain of
M. bovis called BCG (BacillusM. bovis called BCG (Bacillus
Calmette-Guerin) MostCalmette-Guerin) Most
effective againsteffective against
extrapulmonary tuberculosis.extrapulmonary tuberculosis.
Not used in the U.S. though.Not used in the U.S. though.
Sorry!Sorry!
21. Lyme Disease (Lyme Disease (Borrelia burgdoferiBorrelia burgdoferi))
• Helical shaped bacteriaHelical shaped bacteria
• Disease spread by biteDisease spread by bite
from an infected deer tickfrom an infected deer tick
• Enters the bloodstreamEnters the bloodstream
and spreads to differentand spreads to different
organs in the bodyorgans in the body
• Arthritic symptoms andArthritic symptoms and
neurologic symptoms canneurologic symptoms can
develop. Most peopledevelop. Most people
complain of headachescomplain of headaches
and some people developand some people develop
meningitis or encephalitis.meningitis or encephalitis.
22. Immune ResponseImmune Response
• Antibodies to a protein associatedAntibodies to a protein associated
with the flagella ofwith the flagella of B. burgdorferiB. burgdorferi isis
usually detected after infection andusually detected after infection and
may contribute to pathogenesis.may contribute to pathogenesis.
• Antigen-antibody complexes canAntigen-antibody complexes can
activate complement system,activate complement system,
resulting in direct lytic damage toresulting in direct lytic damage to
the joints or vasculature.the joints or vasculature.
• Interleukin 1 (IL-1) said to beInterleukin 1 (IL-1) said to be
involved in pathogenesis of Lymeinvolved in pathogenesis of Lyme
disease, sincedisease, since BorreliaBorrelia has a cellhas a cell
wall containing lipopolysaccharidewall containing lipopolysaccharide
(LPS) and LPS is a well known(LPS) and LPS is a well known
inducer of IL-1inducer of IL-1
• Most humans develop antibodies toMost humans develop antibodies to
a flagellar antigen, while micea flagellar antigen, while mice
develop antibodies to two proteinsdevelop antibodies to two proteins
on the outer surface of the bacterialon the outer surface of the bacterial
envelope.envelope.
23. How do we treat it?How do we treat it?
• Lyme disease can beLyme disease can be
successfully treated withsuccessfully treated with
broad-spectrumbroad-spectrum
antibiotics such asantibiotics such as
penicillin and tetracycline.penicillin and tetracycline.
• A vaccine based onA vaccine based on
outer-surface protein Aouter-surface protein A
suggests that it offerssuggests that it offers
significant protection.significant protection.
The vaccine wasThe vaccine was
approved for use inapproved for use in
January 1999.January 1999.
24. Online Information on LymeOnline Information on Lyme
DiseaseDisease
• http://www.cdc.gov/ncidod/dvbid/lyme/index.hthttp://www.cdc.gov/ncidod/dvbid/lyme/index.ht
– This is just some general info on LymeThis is just some general info on Lyme
DiseaseDisease
• http://phil.cdc.gov/Phil/detail.asp?id=2417http://phil.cdc.gov/Phil/detail.asp?id=2417
– This is a up close and personal picture ofThis is a up close and personal picture of
Borrelia burgdorferiBorrelia burgdorferi